StreetInsider.com News Articles

Lexaria receives $2.6M tax rebate from Australian R&D program

Tue, 01 Sep 2026 09:15:40 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) has received a cash rebate of AUD$3,666,611.98 (approximately USD$2.6 million) from the Australian Tax Office, according to a statement from the company.

The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary, Lexaria (AU) Pty Ltd. The rebate was granted under Australia's Research & Development Tax Incentive Program following a review of the company's 2025 application, which verified compliance with the program's requirements.

The rebate is connected to Lexaria's 12-week chronic GLP-1-H24-4 Study, which the company conducted in Australia. Lexaria said it intends to use the proceeds for future R&D activities in Australia.

"This is

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Tue, 01 Sep 2026 09:15:00 -0400

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate

KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.

Lexaria strategically performed its previous 12-week chronic GLP-1-H24-4 Study in Australia, fully aware of certain potential tax advantages in

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Tue, 01 Sep 2026 09:15:00 -0400

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate

Lexaria strategically performed its previous 12-week chronic GLP-1-H24-4 Study in Australia, fully aware of certain potential tax advantages in

DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Mon, 24 Aug 2026 09:10:00 -0400

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study
Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated
Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs

KELOWNA, BC / ACCESS Newswire / August 24, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that blood plasma pharmacokinetic ("PK")

DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Mon, 24 Aug 2026 09:10:00 -0400

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study
Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated
Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs

Form 8-K Lexaria Bioscience Corp. For: Aug 17

Mon, 17 Aug 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260817/26937000.html

Form 8-K Lexaria Bioscience Corp. For: Aug 17

Mon, 17 Aug 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260817/26937000.html

Lexaria signs material transfer agreement with PegBio for GLP-1 study

Thu, 13 Aug 2026 09:02:16 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) has entered into a Material Transfer Agreement (MTA) with PegBio Co., Ltd (HKG: 2565) to evaluate Lexaria's DehydraTECH drug delivery technology with a proprietary GLP-1 molecule being developed by PegBio.

Under the agreement, PegBio will supply Lexaria with a proprietary GLP-1 molecule, which Lexaria will then process using its patented DehydraTECH technology and evaluate for pharmacokinetic performance in animal studies. Lexaria said the MTA is separate from a pre-existing material transfer agreement it holds with another, unnamed pharmaceutical company.

PegBio is a biotechnology company focused on metabolic and related chronic diseases. Its first internally developed drug, PB-119

Lexaria Enters a Material Transfer Agreement With PegBio

Thu, 13 Aug 2026 09:00:00 -0400

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio Co., Ltd ("PegBio") to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry. Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company.

The MTA details the conditions under which PegBio will supply Lexaria with a proprietary GLP-1

Lexaria Enters a Material Transfer Agreement With PegBio

Thu, 13 Aug 2026 09:00:00 -0400

The MTA details the conditions under which PegBio will supply Lexaria with a proprietary GLP-1

Form 8-K Lexaria Bioscience Corp. For: Aug 04

Mon, 10 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260810/26898965.html

Form 8-K Lexaria Bioscience Corp. For: Aug 04

Mon, 10 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260810/26898965.html

Form 8-K Lexaria Bioscience Corp. For: Jul 29

Thu, 30 Jul 2026 12:03:00 -0400

si-local-file:///var/storage/secattach/20260730/26841690.html

Form 8-K Lexaria Bioscience Corp. For: Jul 29

Thu, 30 Jul 2026 12:03:00 -0400

si-local-file:///var/storage/secattach/20260730/26841690.html

Lexaria Bioscience sets 1-for-15 reverse stock split for Aug. 3

Thu, 30 Jul 2026 11:00:15 -0400

Lexaria Bioscience Corp. (Nasdaq: LEXX) announced a 1-for-15 reverse stock split of its common stock, effective 12:01 a.m. EST on August 3, 2026.

The split will reduce the company's current share count from 24,787,446 shares to approximately 1,652,496 shares, with fractional shares rounded up to the nearest whole number. The number of authorized shares will also be reduced from 220,000,000 to 14,666,667. The par value of shares will remain unchanged.

According to the company, the primary purpose of the action is to raise the per-share market price above the $1.00 minimum bid price required under Nasdaq Listing Rule 5550(a)(2). Lexaria stated it

Lexaria Announces Effective Date for Reverse Stock Split

Thu, 30 Jul 2026 11:00:00 -0400

KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it intends to effect a reverse stock split of its common stock effective as of 12:01 am EST on August 3, 2026 (the "Reverse Split").

The primary goal of the Reverse Split is to increase the per Share market price of the Company's Shares with the objective of regaining compliance with the NASDAQ Capital Market's ("Nasdaq") minimum $1.00 bid price per share requirement of Nasdaq Listing

Lexaria Announces Effective Date for Reverse Stock Split

Thu, 30 Jul 2026 11:00:00 -0400

Form 10-Q Lexaria Bioscience Corp. For: May 31

Mon, 13 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260713/26762714.html

Form 10-Q Lexaria Bioscience Corp. For: May 31

Mon, 13 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260713/26762714.html

Lexaria reports partner meetings at BIO convention in San Diego

Mon, 06 Jul 2026 09:11:02 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) attended the 2026 BIO International Convention in San Diego, where the company held meetings with potential pharmaceutical partners, according to a press release from the company.

Chief Executive Richard Christopher said the company met with a range of firms, from smaller technology-focused companies to large global pharmaceutical companies. "We are balancing new exploratory corporate opportunities with existing corporate relationships, with the intent of entering into partnership arrangements," Christopher said.

The company said most of its current business discussions are related to the GLP-1 sector. Lexaria noted a shift in focus at this year's BIO conference toward drug

Lexaria Updates Business Development

Mon, 06 Jul 2026 09:10:00 -0400

KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO International Convention ("BIO") in San Diego, CA.

"Lexaria had a full schedule at BIO, meeting with a diverse group of companies ranging from innovative smaller tech-focused firms to multi-billion-dollar global pharmaceutical companies," said Richard Christopher, CEO of Lexaria Bioscience Corp. "We are balancing new exploratory corporate opportunities with

Lexaria Updates Business Development

Mon, 06 Jul 2026 09:10:00 -0400

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

Thu, 25 Jun 2026 09:10:00 -0400

KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14^th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo Nordisk's® ("Novo") commercially available Wegovy® tablets, over a 5-week duration (the "Study").

Lexaria is seeking to preserve the superior safety and tolerability profiles evidenced in its previous glucagon-like peptide-1 ("GLP-1") studies such as Human Study #4 (GLP-1-H24-4), combined with pharmacokinetic ("PK")

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

Thu, 25 Jun 2026 09:10:00 -0400

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Tue, 23 Jun 2026 09:25:00 -0400

Potentially Valuable Novel Compositions Being Investigated

Lexaria Also Receives Additional New Granted Patent

KELOWNA, BC / ACCESS Newswire / June 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following update on Animal Study #1 (GLP-1-A26-1) that is evaluating a number of formulation enhancements using both DehydraTECH-semaglutide ("DHT-sema") glucagon-like peptide-1 ("GLP-1") compositions and DehydraTECH-CBD ("DHT-CBD") compositions to explore the potential for additional improved performance as well as stake new intellectual property ("IP") claims (the "Study").

The Study is on schedule and dosing